



AREV LIFE SCIENCES GLOBAL CORP.  
PRESS RELEASE

**Dr. Andrew Levinson Joins AREV Life Sciences Global Corporation  
Scientific Advisory Board**

VANCOUVER, BC / October 28, 2022 / AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) is pleased to announce the appointment of Dr. Andrew Levinson to the company’s Scientific Advisory Board. Dr. Levinson is dedicated to progressive direction in integrative health, Dr. Levinson is a functional medicine doctor and psychiatrist combining mainstream and alternative approaches together with comprehensive treatments. He has developed and commercialized a line of complementary products branded as “Vitality Health and Wellness” which he sells through his clinics and concierge service. The line addresses nutrition and holistic deficiencies in patients.

Dr. Levinson received both his Bachelor of Science in Psychobiology and his Medical Doctorate from University of Miami. While at University of Miami, in 1993 Dr. Levinson created and chaired an alternative medicine conference which was integrated into the medical school’s curriculum for both students and professors. He also pursued academia as an Assistant Professor in the Department of Psychiatry at Florida International University’s College of Medicine. Dr. Levinson has affiliation with; the International AIDS Society (IAS), the International Association of Providers of AIDS Care (IAPAC), the American Academy of HIV Medicine (AAHIVM), and the Infectious Disease Society of America (IDSA).

Following data presented at The 24<sup>th</sup> International AIDS conference (AIDS 2022) in Montreal this past July which demonstrates the significant impact of neuropsychiatric complications of Serious Acute Malnutrition (SAM) both compounded by and exacerbating HIV Associated Neurological Disorder (HAND), AREV Life Sciences expands the capacities of its Scientific Advisory Board.

Clinical research has demonstrated the necessity of affording comprehensive psychiatric evaluations as an essential component of our clinical studies in pediatric populations experiencing SAM,” said Dr. Sateesh Apte, neurologist and AREV Scientific Advisory Board Member. “The psychiatric implications of SAM in pediatric populations is obviously a driving concern in addressing the devastating consequences of neurodegeneration but this morbid condition remains wholly unaddressed in the literature. AREV is committed to developing SUSTAINN™ in studies that complement the development of global agendas on mental health and food security and nutrition.

“AREV is enthusiastic about the addition of Dr. Levinson and his extensive experience in integrative psychiatry as we work to bring products to market within lower-to-middle-income countries (LMICs) as well as our wellness categories of therapeutic nutrition” said AREV Chairman and CEO Mike Withrow. The evolution of AREV’s clinical nutrition pipeline, including our enteral formula Re-Store™ and SUSTAINN™, our next generation ready-to-use therapeutic food (RUTF).

“The collective psychiatric impact of SAM obviously is accompanied by pediatric trauma of egregious proportion with a multitude of studies showing associations between poor mental health and malnutrition, low intake of certain nutrients and Body Mass Index” said Dr. Levinson. “ AREV’s development of SUSTAINN™ is providing the psychiatric community insight into the appropriate clinical management of tens of millions of patients the throughout resource-challenged nations at a historical point when famine and food insecurity is affecting the survival as well the cognitive development of children in Asia, Africa, the Middle East, and Pacific Island nations.”

AREV’s initial concept sheets which are being submitted to publicly sponsored clinical research networks, that are corresponding with public health commodity procurement programs, is intended to demonstrate the superiority of SUSTAINN™ in clinical trials measuring its efficacy against standard of care for addressing SAM in pediatric populations in LMIC settings. The United Nations International Children’s Emergency Fund (UNICEF) procures an estimated 75- 80 per cent of the global demand for RUTF, averaging 49,000 metric tons (MT) per year over the last four years, suitable to treat 3.5 million children. The Global Nutrition report in 2017 made a clear case

for the importance of improving nutrition in achieving at least five Sustainable Development Goals (SDG) of the UN's Development Agenda. (source: <https://www.unicef.org/supply/media/7256/file/RUTF-Supply-Update-March-2021.pdf>)

AREV Scientific Advisory Board Chairman and former United States Assistant Surgeon General Roscoe Moore, DVM, MPH, PhD, said “Dr Levenson’s appointment expands AREV’s capacity to better design our clinical studies on SUSTAINN™ in LMIC pediatric patient populations vulnerable to cognitive damage due to serious acute malnutrition, being launched in coordination with our academic and industry partners”.

About SUSTAINN™, AREV’s Ready-to-Use Therapeutic Food (RUTF)

SUSTAINN™ (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs) is a next generation RUTF being developed by AREV Life Sciences, based in Vancouver. This initiative aims to demonstrate the delivery of measurable therapeutic effect in forthcoming inferiority/superiority studies through a unique next-generation RUTF composition. SUSTAINN™ is intended to treat inanition, the complex disease state that is currently the culprit in the deaths of nine million people worldwide annually, more than the death toll of AIDS, malaria, and tuberculosis combined. Inanition is clinically characterized by dysbiosis, environmental enteropathy, neurodegenerative disease, organ failure, scurvy, beriberi, Kwashiorkor, and anemia due to SAM.

SUSTAINN™ is being developed in collaboration with The Richardson Centre for Food Technology and Research, University of Manitoba, TransBiotech, and key opinion leaders in biology, therapeutic development and clinical study design from the Institute of Human Virology, University of Maryland and The Linus Pauling Center at Oregon State University, is in compliance with WHO, and Codex-Alimentary guidelines in 43 countries. RUTF’s are essential therapeutic interventions for the treatment of severe acute malnutrition and currently account for more than US \$440M in 2022 in sales by more than 40 companies. SUSTAINN™ is being produced under GMP conditions, which meet relevant export criteria, is aflatoxin free and designed to maintain a shelf life of up to two years under appropriate storage instructions. SUSTAINN™ provides optimal nutritional support addressing the restoration of gut microbiota, malabsorption associated with cachexia, provides essential nutrition, vitamins, minerals and protein that encourage muscle retention, and metabolic functions including ATP levels and EFA supplementation that encourages neurological development. Further collaborations are in development following meetings at AIDS 2022 with AREV Executive leadership and key opinion leaders in positions of program leadership at PEPFAR, the Global Fund for AIDS TB and Malaria, UNAIDS USAID and the World Food Program.

Further, the Company is pleased to announce that the Company has issued 100,000 stock options to Directors, Officers and Consultants of the Company at a price of \$0.12 for a period of 5 years from the issuance dated. These options will vest immediately.

AREV Life Sciences Global Corporation also announces today the resignation of Kevin Phelps as COO and the settlement of debt with Nava Financial Inc.

The Company announces the resignation of Mr. Kevin Phelps as Chief Operating Officer (“COO”) of the Company. Mr. Phelps feels that the Company is at a critical step in its development, and onsite leadership is needed at this time. Due to Mr. Phelps being located in New York, and given the challenges of International travel given the pandemic, he was no longer the best fit for this role. Mr. Phelps will continue on as a member of the Board of Directors of the Company. The Company would like to thank Mr. Phelps for his efforts at COO.

The Company is also pleased to announce it has settled \$9,000 in debt with Nava Financial Inc., by the issuance of 75,000 Shares at \$0.12.

For further information, contact Mike Withrow, [mike@AREVBrands.com](mailto:mike@AREVBrands.com) 778-929-6536. For more information visit <https://www.arelifesciences.com/>.

On behalf of the Board,

Mike Withrow  
CEO & Director



## About AREV Life Sciences Global Corp.

The Company is a fully integrated enterprise with competencies in: 1) extraction of compounds for consumption and topical use. 2) Clinical Nutrition and 3) A technology platform called Medicine Merchant. The Company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company's business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage.

AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECANADA and The Biotechnology Innovation Organization (BIO).

**NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**

## FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com).